| Wal-mart Pharmacy 10-0339 | |
| 1123 Highway 79 167 Byp, Fordyce, Arkansas 71742 | |
| (870) 352-8034 |
| Name | Wal-mart Pharmacy 10-0339 |
|---|---|
| Organization Name | Walmart Inc |
| Location | 1123 Highway 79 167 Byp, Fordyce, Arkansas 71742 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Phone | (870) 352-8034 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
Abbott announced today an exclusive worldwide licensing agreement with Pierre Fabre SA to develop and commercialize h224G11, a pre-clinical monoclonal antibody identified at the Centre d'Immunologie Pierre Fabre (CIPF) in France and targeting the cMet receptor for the treatment of cancer.
The National Comprehensive Cancer Network Oncology Research Program today announced plans to support a phase II randomized trial for lung cancer patients.
Investigators in The Research Institute at Nationwide Children's Hospital have identified the role of a protein that could potentially lead to new clinical treatments to combat musculoskeletal diseases, including Duchenne muscular dystrophy (DMD).
INSYS Therapeutics, Inc. announces positive results from the pivotal phase III efficacy trial for patients utilizing the Fentanyl Sublingual Spray technology to treat breakthrough cancer pain. All primary and secondary endpoints were achieved in the study, and the drug is the first product to ever show statistically significant pain relief when measuring the summary of pain intensity difference at five minutes in a phase III breakthrough cancer pain trial using Fentanyl.
Growing evidence suggests that SARS-CoV-2, the novel coronavirus that causes COVID-19, can be spread by asymptomatic people via aerosols - a reality that deeply underscores the ongoing importance of regular widespread testing, wearing masks and physical distancing to reduce the spread of the virus, say Kimberly Prather and colleagues in a new Perspective.
› Verified 6 days ago
| NPI Number | 1235156639 |
| Organization Name | WALMART INC. |
| Doing Business As | WALMART PHARMACY 10-0339 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Address | 1123 Highway 79 167 Byp, Fordyce, AR 71742 |
| Phone Number | 870-352-8034 |
News Archive
Abbott announced today an exclusive worldwide licensing agreement with Pierre Fabre SA to develop and commercialize h224G11, a pre-clinical monoclonal antibody identified at the Centre d'Immunologie Pierre Fabre (CIPF) in France and targeting the cMet receptor for the treatment of cancer.
The National Comprehensive Cancer Network Oncology Research Program today announced plans to support a phase II randomized trial for lung cancer patients.
Investigators in The Research Institute at Nationwide Children's Hospital have identified the role of a protein that could potentially lead to new clinical treatments to combat musculoskeletal diseases, including Duchenne muscular dystrophy (DMD).
INSYS Therapeutics, Inc. announces positive results from the pivotal phase III efficacy trial for patients utilizing the Fentanyl Sublingual Spray technology to treat breakthrough cancer pain. All primary and secondary endpoints were achieved in the study, and the drug is the first product to ever show statistically significant pain relief when measuring the summary of pain intensity difference at five minutes in a phase III breakthrough cancer pain trial using Fentanyl.
Growing evidence suggests that SARS-CoV-2, the novel coronavirus that causes COVID-19, can be spread by asymptomatic people via aerosols - a reality that deeply underscores the ongoing importance of regular widespread testing, wearing masks and physical distancing to reduce the spread of the virus, say Kimberly Prather and colleagues in a new Perspective.
› Verified 6 days ago
News Archive
Abbott announced today an exclusive worldwide licensing agreement with Pierre Fabre SA to develop and commercialize h224G11, a pre-clinical monoclonal antibody identified at the Centre d'Immunologie Pierre Fabre (CIPF) in France and targeting the cMet receptor for the treatment of cancer.
The National Comprehensive Cancer Network Oncology Research Program today announced plans to support a phase II randomized trial for lung cancer patients.
Investigators in The Research Institute at Nationwide Children's Hospital have identified the role of a protein that could potentially lead to new clinical treatments to combat musculoskeletal diseases, including Duchenne muscular dystrophy (DMD).
INSYS Therapeutics, Inc. announces positive results from the pivotal phase III efficacy trial for patients utilizing the Fentanyl Sublingual Spray technology to treat breakthrough cancer pain. All primary and secondary endpoints were achieved in the study, and the drug is the first product to ever show statistically significant pain relief when measuring the summary of pain intensity difference at five minutes in a phase III breakthrough cancer pain trial using Fentanyl.
Growing evidence suggests that SARS-CoV-2, the novel coronavirus that causes COVID-19, can be spread by asymptomatic people via aerosols - a reality that deeply underscores the ongoing importance of regular widespread testing, wearing masks and physical distancing to reduce the spread of the virus, say Kimberly Prather and colleagues in a new Perspective.
› Verified 6 days ago
Wal-mart Pharmacy 10-0339 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 1123 Highway 79 167 Byp, Fordyce, Arkansas 71742 Phone: (870) 352-8034 |